Sinotherapeutics Inc. (SHA:688247)
China
· Delayed Price · Currency is CNY 10.25
-0.12 (-1.16%)
Mar 13, 2025, 4:00 PM CST
Sinotherapeutics Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2018 |
| Cash & Equivalents | - | 641.78 | 763.15 | 511.66 | 434.17 | Upgrade
|
| Short-Term Investments | - | 107.21 | 44.09 | - | - | Upgrade
|
| Cash & Short-Term Investments | 747.64 | 748.99 | 807.23 | 511.66 | 434.17 | Upgrade
|
| Cash Growth | -0.18% | -7.21% | 57.77% | 17.85% | 68.23% | Upgrade
|
| Accounts Receivable | - | 78.47 | 71.27 | 44.09 | 35.84 | Upgrade
|
| Other Receivables | - | 0.57 | - | - | 10.54 | Upgrade
|
| Receivables | - | 79.04 | 71.27 | 44.09 | 46.38 | Upgrade
|
| Inventory | - | 84.61 | 29.38 | 40.43 | 41.81 | Upgrade
|
| Other Current Assets | - | 39.37 | 45.83 | 22.66 | 23.64 | Upgrade
|
| Total Current Assets | - | 952.01 | 953.71 | 618.83 | 546 | Upgrade
|
| Property, Plant & Equipment | - | 271.41 | 255.92 | 115.09 | 105.72 | Upgrade
|
| Long-Term Investments | - | 64.2 | 49.1 | 69.99 | 7.86 | Upgrade
|
| Goodwill | - | 18.39 | 18.39 | - | - | Upgrade
|
| Other Intangible Assets | - | 27.59 | 32.47 | 41.16 | 51.58 | Upgrade
|
| Long-Term Deferred Tax Assets | - | 14.29 | 16.45 | 16.08 | 14.44 | Upgrade
|
| Long-Term Deferred Charges | - | 1.21 | 1.99 | 3.15 | 3.81 | Upgrade
|
| Other Long-Term Assets | - | 12.54 | 4.3 | 1.5 | 9.39 | Upgrade
|
| Total Assets | - | 1,362 | 1,332 | 865.81 | 738.8 | Upgrade
|
| Accounts Payable | - | 13.34 | 8.42 | 8.01 | 5.39 | Upgrade
|
| Accrued Expenses | - | 14.69 | 11.58 | 14.19 | 32.15 | Upgrade
|
| Current Portion of Leases | - | 0.06 | 0.32 | 0.78 | - | Upgrade
|
| Current Income Taxes Payable | - | 1.28 | 0.45 | 7.85 | - | Upgrade
|
| Current Unearned Revenue | - | 48.01 | 56.8 | 46.78 | 95.51 | Upgrade
|
| Other Current Liabilities | - | 13.33 | 12.47 | 11.92 | 9.48 | Upgrade
|
| Total Current Liabilities | - | 90.72 | 90.05 | 89.52 | 142.54 | Upgrade
|
| Long-Term Leases | - | 0.02 | 1.2 | 3.66 | - | Upgrade
|
| Long-Term Unearned Revenue | - | 58.09 | 61.12 | 64.62 | 30.93 | Upgrade
|
| Long-Term Deferred Tax Liabilities | - | 2.53 | 2.68 | 2.82 | 2.96 | Upgrade
|
| Total Liabilities | - | 151.36 | 155.05 | 160.62 | 176.42 | Upgrade
|
| Common Stock | - | 453.34 | 453.34 | 408 | 408 | Upgrade
|
| Additional Paid-In Capital | - | 512.89 | 512.89 | 179.23 | 171.29 | Upgrade
|
| Retained Earnings | - | 244.16 | 211.19 | 118.26 | -16.66 | Upgrade
|
| Comprehensive Income & Other | - | -0.13 | -0.15 | -0.31 | -0.26 | Upgrade
|
| Shareholders' Equity | 1,237 | 1,210 | 1,177 | 705.19 | 562.38 | Upgrade
|
| Total Liabilities & Equity | - | 1,362 | 1,332 | 865.81 | 738.8 | Upgrade
|
| Total Debt | 0.02 | 0.09 | 1.52 | 4.44 | - | Upgrade
|
| Net Cash (Debt) | 747.61 | 748.91 | 805.71 | 507.22 | 434.17 | Upgrade
|
| Net Cash Growth | -0.17% | -7.05% | 58.85% | 16.82% | 68.23% | Upgrade
|
| Net Cash Per Share | 1.63 | 1.59 | 1.91 | 1.24 | 1.06 | Upgrade
|
| Filing Date Shares Outstanding | 509.45 | 449.15 | 453.34 | 408 | 408 | Upgrade
|
| Total Common Shares Outstanding | 449 | 453.34 | 453.34 | 408 | 408 | Upgrade
|
| Working Capital | - | 861.29 | 863.66 | 529.31 | 403.47 | Upgrade
|
| Book Value Per Share | 2.76 | 2.67 | 2.60 | 1.73 | 1.38 | Upgrade
|
| Tangible Book Value | 1,196 | 1,164 | 1,126 | 664.02 | 510.79 | Upgrade
|
| Tangible Book Value Per Share | 2.66 | 2.57 | 2.48 | 1.63 | 1.25 | Upgrade
|
| Buildings | - | 211.68 | 54.29 | 52.41 | 45.57 | Upgrade
|
| Machinery | - | 160.89 | 145.6 | 135.93 | 117.73 | Upgrade
|
| Construction In Progress | - | 15.35 | 153.61 | 4.68 | 9.32 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.